CA2433866A1 - Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists - Google Patents
Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists Download PDFInfo
- Publication number
- CA2433866A1 CA2433866A1 CA002433866A CA2433866A CA2433866A1 CA 2433866 A1 CA2433866 A1 CA 2433866A1 CA 002433866 A CA002433866 A CA 002433866A CA 2433866 A CA2433866 A CA 2433866A CA 2433866 A1 CA2433866 A1 CA 2433866A1
- Authority
- CA
- Canada
- Prior art keywords
- dao
- substituted
- alkyl
- compound
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26188301P | 2001-01-16 | 2001-01-16 | |
| US60/261,883 | 2001-01-16 | ||
| US30544501P | 2001-07-13 | 2001-07-13 | |
| US60/305,445 | 2001-07-13 | ||
| US34521101P | 2001-10-22 | 2001-10-22 | |
| US60/345,211 | 2001-10-22 | ||
| US33388101P | 2001-11-19 | 2001-11-19 | |
| US60/333,881 | 2001-11-19 | ||
| PCT/IB2002/001262 WO2002066672A2 (en) | 2001-01-16 | 2002-01-15 | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2433866A1 true CA2433866A1 (en) | 2002-08-29 |
Family
ID=27500728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002433866A Abandoned CA2433866A1 (en) | 2001-01-16 | 2002-01-15 | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1412515A2 (pt) |
| JP (1) | JP2004537275A (pt) |
| KR (1) | KR20030066813A (pt) |
| CN (1) | CN1568370A (pt) |
| AU (1) | AU2002247939B2 (pt) |
| BR (1) | BR0206495A (pt) |
| CA (1) | CA2433866A1 (pt) |
| EA (1) | EA006654B1 (pt) |
| IL (1) | IL156865A0 (pt) |
| MX (1) | MXPA03006321A (pt) |
| WO (1) | WO2002066672A2 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE408593T1 (de) | 2001-05-03 | 2008-10-15 | Galileo Lab Inc | Pyruvatderivate |
| EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| WO2003039540A2 (en) * | 2001-11-09 | 2003-05-15 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
| WO2003047558A2 (en) * | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| US20060234221A1 (en) * | 2001-12-12 | 2006-10-19 | Genset S.A. | Biallelic markers of d-amino acid oxidase and uses thereof |
| EP1495041A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA interferon-mediated inhibition of gene expression of G72 and D-amino acid oxidase (DAAO) using short-term interfering nucleic acid (siNA) |
| GB0223424D0 (en) * | 2002-10-09 | 2002-11-13 | Imp College Innovations Ltd | Disease-associated gene |
| BRPI0418244A (pt) | 2003-12-29 | 2007-04-17 | Sepracor Inc | composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica |
| WO2007082208A2 (en) * | 2006-01-09 | 2007-07-19 | Oklahoma Medical Research Foundation | Lanthionine-related compounds for the treatment of inflammatory diseases |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| GB2456390A (en) * | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| US9649304B2 (en) | 2009-01-20 | 2017-05-16 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| JP4462382B1 (ja) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤 |
| WO2012135119A1 (en) * | 2011-03-25 | 2012-10-04 | Genomind, Llc | Biomarker-based detection and treatment of neurodegenerative depression |
| EP2831232A4 (en) | 2012-03-30 | 2015-11-04 | Univ Washington | METHODS OF MODULATING THE EXPRESSION OF TAU TO REDUCE THE STROKE AND MODIFY A NEURODEGENERATIVE SYMPTOM |
| RU2765625C2 (ru) | 2016-06-13 | 2022-02-01 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
| EP3468944B1 (en) | 2016-06-13 | 2022-11-16 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| CN108504752B (zh) * | 2018-06-26 | 2021-05-11 | 华中农业大学 | 一种与母猪繁殖性状关联的分子标记及应用 |
| CN111909907B (zh) * | 2020-07-08 | 2022-05-24 | 浙江工业大学 | 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| CA2361408A1 (en) * | 1999-03-30 | 2000-10-05 | Genset S.A. | Schizophrenia associated genes, proteins and biallelic markers |
| AU6462500A (en) * | 1999-07-29 | 2001-02-19 | Patrick T. Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
-
2002
- 2002-01-15 WO PCT/IB2002/001262 patent/WO2002066672A2/en active Application Filing
- 2002-01-15 AU AU2002247939A patent/AU2002247939B2/en not_active Ceased
- 2002-01-15 MX MXPA03006321A patent/MXPA03006321A/es unknown
- 2002-01-15 JP JP2002566376A patent/JP2004537275A/ja active Pending
- 2002-01-15 EP EP02717019A patent/EP1412515A2/en not_active Withdrawn
- 2002-01-15 CA CA002433866A patent/CA2433866A1/en not_active Abandoned
- 2002-01-15 CN CNA028066650A patent/CN1568370A/zh active Pending
- 2002-01-15 KR KR10-2003-7009412A patent/KR20030066813A/ko not_active Application Discontinuation
- 2002-01-15 BR BR0206495-2A patent/BR0206495A/pt not_active IP Right Cessation
- 2002-01-15 EA EA200300807A patent/EA006654B1/ru not_active IP Right Cessation
- 2002-01-15 IL IL15686502A patent/IL156865A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002247939B2 (en) | 2007-01-25 |
| MXPA03006321A (es) | 2003-10-06 |
| BR0206495A (pt) | 2006-01-24 |
| CN1568370A (zh) | 2005-01-19 |
| WO2002066672A3 (en) | 2004-02-26 |
| JP2004537275A (ja) | 2004-12-16 |
| IL156865A0 (en) | 2004-02-08 |
| KR20030066813A (ko) | 2003-08-09 |
| EA200300807A1 (ru) | 2004-08-26 |
| EA006654B1 (ru) | 2006-02-24 |
| AU2002247939B9 (en) | 2002-09-04 |
| EP1412515A2 (en) | 2004-04-28 |
| WO2002066672A2 (en) | 2002-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2433866A1 (en) | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists | |
| US20030185754A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| Nurmi et al. | Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F] CFT | |
| Hirose et al. | A novel mutation of KCNQ3 (c. 925T→ C) in a Japanese family with benign familial neonatal convulsions | |
| Van Den Brink et al. | Identification of PEX7 as the second gene involved in Refsum disease | |
| Blakely et al. | MPV17 mutation causes neuropathy and leukoencephalopathy with multiple mtDNA deletions in muscle | |
| AU2002247939A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| Chen et al. | Antibodies to glutamic acid decarboxylase in Australian children with insulin-dependent diabetes mellitus and their first-degree relatives | |
| US20030166554A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| CN107602690B (zh) | 肺动脉高压相关的ptgis基因突变及其应用 | |
| US6248528B1 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
| Vallat et al. | Myelin widenings and MGUS‐IgA: an immunoelectron microscopic study | |
| Di Blasi et al. | Partial laminin α2 chain deficiency in a patient with myopathy resembling inclusion body myositis | |
| Berg et al. | Changes of copper‐transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult‐onset dystonia | |
| WO1997018230A1 (en) | Cloning and expression of beta app-c100 receptor (c100-r) | |
| US6368797B1 (en) | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant GPIIIa and/or variant BPIIb allele | |
| AU2002339698B2 (en) | Biallelic markers of D-amino acid oxidase and uses thereof | |
| Satoi et al. | Decreased cerebrospinal fluid levels of β‐phenylethylamine in patients with Rett syndrome | |
| US8067158B2 (en) | Methods and compositions for the diagnosis and treatment of schizophrenia | |
| Fujioka et al. | Molecular characterisation of glutamate dehydrogenase gene defects in Japanese patients with congenital hyperinsulinism/hyperammonaemia | |
| WO2009037481A1 (en) | Methods for diagnosing and treating dementia | |
| US6323244B1 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
| Eggers et al. | Rapid clearance of human immunodeficiency virus type 1 from ventricular cerebrospinal fluid during antiretroviral treatment | |
| Gaymard et al. | A common mechanism for the control of eye and head movements in humans | |
| US20040138441A1 (en) | Novel gene functionally related to dyslexia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |